Pharma Focus Asia

Cambrex to Expand Large Scale API Manufacturing Capacity in US


Cambrex plans to invest US$50 million to expand new mid-scale and large-scale API manufacturing capacity. The site will be located in Iowa, US.


The large scale API manufacturing capacity will be constructed with an area covering 45-acre land space. This new capacity will support the development and production of small molecule drug substances.

The expansion features an addition of 3 large-scale manufacturing work centers and 1 mid-scale work center to the facility in Iowa by significantly enhancing the site’s overall capacity to 30 per cent.

This expansion would be the sixth major expansion of the company in the past eight years.

The API manufacturing capacity all set to open in early 2022 will meet the customer needs. Once the expansion is done it is expected to provide job opportunities for 400 new employees.


TypeNew Construction
BudgetUS$50 million
Latest Issue
Get instant
access to our latest e-book
MFA + MMA 2024CPHI Chine || PMEC China 2024Asia Healthcare Week 2024Gibco Adherent Kidney Media PanelCPHI Korea 2024Equinix accelerated medical research...CHEMICAL INDONESIA 2024Thermofisher - Antibody Therapeutic PolishingINALAB 2024 Thermo Scientific - DynaDrive and DynaSpinDigital Health Asia 2024Rehab Expo 2024ISPE Singapore Affiliate Conference & Exhibition 20242024 PDA Pharmaceutical Manufacturing & Quality Conference2024 PDA Cell and Gene Pharmaceutical Products Conference 2024 PDA Aseptic Manufacturing Excellence Conference2024 PDA Aseptic Processing of Biopharmaceuticals ConferencePharma Quality Excellence Awards 20244th Annual Pharma GMP Quality Management 20243rd World ADC Asia 2024
Searching for an end-to-end patient tech solution?